Report Description
Prenatal & Newborn Genetic Testing Market Outlook
The Prenatal & Newborn Genetic Testing Market size was USD 5.45 Billion in 2022 and is likely to reach USD 14.52 Billion by 2031, expanding at a CAGR of 11.5% during 2023–2031.
The genetic disorders such as Down’s syndrome, cystic fibrosis, Tay-Sachs disease, phenylketonuria (PKU), and sickle cell disease are observed among the children of a family irrespective of their health conditions. Prenatal and newborn genetic tests are diagnostic tests for early detection to determine whether the baby is vulnerable to develop such conditions due to genetic disorders.
The tests are used to identify the possible health condition of a baby before and after the baby is born. In other words, the tests are primarily conducted to make better healthcare decisions for the baby as these tests provide accurate information about baby’s health and of mother. These tests examine the identification of genetic disorders in infants at the time of birth along with proper early treatment so that they lead a healthy and productive life.
As per the report published by the World Health Organization (WHO) in 2016, around 8 million infants around the globe were diagnosed with inborn genetic defects. Additionally, as per the Centers for Disease Control and Prevention (CDC), every one in 33 babies suffer from birth defects in the US. The Down syndrome happens to one in 691 infants in the US, according to CDC’s data of year 2017.
Market Trends, Drivers, Restraints, and Opportunities
- High disease prevalence along extensive research and development activities in the field with new drug discovery is driving the market growth.
- Heavy investments in the diagnosis and treatment of diseases by several major market players are propelling the market expansion.
- Increasing awareness of the population related to the diseases and benefits regarding early diagnosis are expected to boost the market growth during the forecast period.
- Rising demand for detecting genetic abnormalities as well as sex determination of fetus before eight to 11 months gestation are pushing towards positive growth of the market.
- Ethical concerns about the testing of new-born and prenatal is proved to be a major challenge that can restrain the market expansion in the coming years.
- Increasing incidence of false or inaccurate results in the testing is hampering the market growth.
- High prevalence, increased awareness, government initiatives, and R&D activities are offering huge opportunities for the market growth in the coming years.
Scope of Prenatal & Newborn Genetic Testing Market Report
The report on the global prenatal & newborn genetic testing market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes
|
Details
|
Report Title
|
Prenatal & Newborn Genetic Testing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
Base Year
|
2022
|
Historic Data
|
2016–2021
|
Forecast Period
|
2023–2031
|
Segmentation
|
Technology (Diagnostics Methods [Polymerase Chain Reaction, Array-comparative Genetic Hybridization, and Fluorescence In-situ Hybridization] and Screening Techniques [Non-invasive Prenatal Tests {Verifi, Harmony, Maternit21 Plus, Panorama, Prena Test, and Bambni Test} and Maternal Serum Screening])
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
Key Players Covered in the Report
|
Bio-Rad Laboratories Inc.; Agilent Technologies Inc.; Illumina, Inc.; and Natera Inc.
|
Prenatal & Newborn Genetic Testing Market Segment Insights
Diagnostics segment is expected to grow at a rapid pace
Based on technology, the global prenatal & newborn genetic testing market is bifurcated into diagnostics methods and screening techniques. The diagnostics segment is further classified into array-comparative genetic hybridization, polymerase chain reaction, and fluorescence in-situ hybridization. The screening techniques segment is further bifurcated into non-invasive prenatal tests and maternal serum screening.
The non-invasive prenatal tests is sub-segregated into maternit21 plus, verifi, harmony, prena test, panorama, and bambni test.
The diagnostics segment is expected to grow at a rapid pace during the forecast period owing to the high prevalence of diseases and increasing government initiatives in the field. Moreover, heavy investments in the R&D activities by the major players for enhancing diagnostic techniques is propelling the segment growth substantially. The screening techniques segment, however, is expected to grow at considerable CAGR during the forecast period due to increased awareness about the disease and increased demand for screening.
North America is anticipated to constitute a key market share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the projected period owing to high population and high quality research in the region. Furthermore, high investment by government and non-government organizations for R&D activities as well as strong pipeline of new products are boosting the market expansion of the region.
On the other hand, the Asia Pacific market is anticipated to expand at a significant growth rate in the near future owing to the high number of cases in the region and growing awareness about the importance of early diagnostics among a large number of the population in the region. Government policies and developing healthcare facilities present key factors for development of the regional market.
Segments
The global prenatal & newborn genetic testing market has been segmented on the basis of
Technology
- Diagnostics Methods
- Polymerase Chain Reaction
- Array-comparative Genetic Hybridization
- Fluorescence In-situ Hybridization
- Screening Techniques
- Non-invasive Prenatal Tests
- Verifi
- Harmony
- Maternit21 Plus
- Panoramal
- Prena Test
- Bambni Test
- Maternal Serum Screening
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
Competitive Landscape
The key players competing in the global prenatal & newborn genetic testing market are Bio-Rad Laboratories Inc.; Agilent Technologies Inc.; Illumina, Inc.; and Natera Inc. Some of these players are actively engaged in several market development strategies such as new product launching, entering into collaboration and partnership, and production capacity expansion to enhance their market share and expand their geographical reach.
Table Of Content
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Prenatal & Newborn Genetic Testing Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Prenatal & Newborn Genetic Testing Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Prenatal & Newborn Genetic Testing Market - Supply Chain
4.5. Global Prenatal & Newborn Genetic Testing Market Forecast
4.5.1. Prenatal & Newborn Genetic Testing Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Prenatal & Newborn Genetic Testing Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Prenatal & Newborn Genetic Testing Market Absolute $ Opportunity
5. Global Prenatal & Newborn Genetic Testing Market Analysis and Forecast by Region
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Region
5.2.2. Y-o-Y Growth Projections by Region
5.3. Prenatal & Newborn Genetic Testing Market Size and Volume Forecast by Region
5.3.1. North America
5.3.2. Latin America
5.3.3. Europe
5.3.4. Asia Pacific
5.3.5. Middle East and Africa (MEA)
5.4. Absolute $ Opportunity Assessment by Region
5.5. Market Attractiveness/Growth Potential Analysis by Region
5.6. Global Prenatal & Newborn Genetic Testing Demand Share Forecast, 2019-2026
6. North America Prenatal & Newborn Genetic Testing Market Analysis and Forecast
6.1. Introduction
6.1.1. Basis Point Share (BPS) Analysis by Country
6.1.2. Y-o-Y Growth Projections by Country
6.2. North America Prenatal & Newborn Genetic Testing Market Size and Volume Forecast by Country
6.2.1. U.S.
6.2.2. Canada
6.3. Absolute $ Opportunity Assessment by Country
6.4. Market Attractiveness/Growth Potential Analysis
6.4.1. By Country
6.4.2. By Product Type
6.4.3. By Application
6.5. North America Prenatal & Newborn Genetic Testing Demand Share Forecast, 2019-2026
7. Latin America Prenatal & Newborn Genetic Testing Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.1.3. Latin America Average Pricing Analysis
7.2. Latin America Prenatal & Newborn Genetic Testing Market Size and Volume Forecast by Country
7.2.1. Brazil
7.2.2. Mexico
7.2.3. Rest of Latin America
7.3. Absolute $ Opportunity Assessment by Country
7.4. Market Attractiveness/Growth Potential Analysis
7.4.1. By Country
7.4.2. By Product Type
7.4.3. By Application
7.5. Latin America Prenatal & Newborn Genetic Testing Demand Share Forecast, 2019-2026
8. Europe Prenatal & Newborn Genetic Testing Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Europe Average Pricing Analysis
8.2. Europe Prenatal & Newborn Genetic Testing Market Size and Volume Forecast by Country
8.2.1. Germany
8.2.2. France
8.2.3. Italy
8.2.4. U.K.
8.2.5. Spain
8.2.6. Russia
8.2.7. Rest of Europe
8.3. Absolute $ Opportunity Assessment by Country
8.4. Market Attractiveness/Growth Potential Analysis
8.4.1. By Country
8.4.2. By Product Type
8.4.3. By Application
8.5. Europe Prenatal & Newborn Genetic Testing Demand Share Forecast, 2019-2026
9. Asia Pacific Prenatal & Newborn Genetic Testing Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Asia Pacific Average Pricing Analysis
9.2. Asia Pacific Prenatal & Newborn Genetic Testing Market Size and Volume Forecast by Country
9.2.1. China
9.2.2. Japan
9.2.3. South Korea
9.2.4. India
9.2.5. Australia
9.2.6. Rest of Asia Pacific (APAC)
9.3. Absolute $ Opportunity Assessment by Country
9.4. Market Attractiveness/Growth Potential Analysis
9.4.1. By Country
9.4.2. By Product Type
9.4.3. By Application
9.5. Asia Pacific Prenatal & Newborn Genetic Testing Demand Share Forecast, 2019-2026
10. Middle East & Africa Prenatal & Newborn Genetic Testing Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Middle East & Africa Average Pricing Analysis
10.2. Middle East & Africa Prenatal & Newborn Genetic Testing Market Size and Volume Forecast by Country
10.2.1. Saudi Arabia
10.2.2. South Africa
10.2.3. UAE
10.2.4. Rest of Middle East & Africa (MEA)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Market Attractiveness/Growth Potential Analysis
10.4.1. By Country
10.4.2. By Product Type
10.4.3. By Application
10.5. Middle East & Africa Prenatal & Newborn Genetic Testing Demand Share Forecast, 2019-2026
11. Competition Landscape
11.1. Global Prenatal & Newborn Genetic Testing Market: Market Share Analysis
11.2. Prenatal & Newborn Genetic Testing Distributors and Customers
11.3. Prenatal & Newborn Genetic Testing Market: Competitive Dashboard
11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
11.4.1. Bio-Rad Laboratories Inc.
11.4.2.
Agilent Technologies Inc.
11.4.3.
Illumina, Inc.
11.4.4.
Natera Inc.